All In Biotech

Drug Trial Radar · NCT01932970

Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide

A Multicenter, Multiple-dose, Single-arm Study to Switch Hemodialysis Subjects With Secondary Hyperparathyroidism From Oral Cinacalcet HCl to Intravenous AMG 416

Last checked: Nov 20, 2026Latest source record: Oct 17, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

158

Actual

Start

Aug 12, 2013

Primary completion

Jan 14, 2014

Study completion Feb 14, 2017

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Aug 30, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, multiple-dose, single-arm, open-label study to assess the impact on serum corrected calcium levels when switching patients from cinacalcet to etelcalcetide (AMG 416).

Conditions

  • Hyperparathyroidism, Secondary

Interventions

  • EtelcalcetideDrug

    Etelcalcetide is provided as a sterile lyophilized powder to be reconstituted with sterile water for injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Serum Corrected Calcium < 7.5 mg/dL During the 4-week Treatment PeriodTime frame: 4 weeks

Locations

40 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Alhambra, California

  • Research Site

    Azusa, California

  • Research Site

    Bakersfield, California

  • Research Site

    Chula Vista, California

  • Research Site

    La Mesa, California

  • Research Site

    Los Angeles, California

  • Research Site

    Lynwood, California

  • Research Site

    Riverside, California

  • Research Site

    Whittier, California

  • Research Site

    Arvada, Colorado

  • Research Site

    North Haven, Connecticut

  • Research Site

    Coral Springs, Florida

  • Research Site

    Hollywood, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Pembroke Pines, Florida

  • Research Site

    Pinecrest, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Augusta, Georgia

  • Research Site

    Evergreen Park, Illinois

  • Research Site

    Michigan City, Indiana

  • Research Site

    Baton Rouge, Louisiana

  • Research Site

    Lafayette, Louisiana

  • Research Site

    Columbus, Mississippi

  • Research Site

    Gulfport, Mississippi

  • Research Site

    Farmington, Missouri

  • Research Site

    Kansas City, Missouri

  • Research Site

    St Louis, Missouri

  • Research Site

    Portsmouth, New Hampshire

  • Research Site

    Eatontown, New Jersey

  • Research Site

    College Point, New York

  • Research Site

    Oklahoma City, Oklahoma

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Orangeburg, South Carolina

  • Research Site

    Arlington, Texas

  • Research Site

    Greenville, Texas

  • Research Site

    Houston, Texas

  • Research Site

    McAllen, Texas

  • Research Site

    San Antonio, Texas

  • Research Site

    Fairfax, Virginia

  • Research Site

    Hampton, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.